aTYR PHARMA INC (ATYR) - Dilution Analysis

10-Q filing | 98.0M shares outstanding

10-Q filing | 97.2M shares outstanding

S-3 filing: The filing is an S-3 form indicating that the company may offer and sell up to $300,000,000 of any combination of common stock, preferred stock, and debt securities.

10-Q filing | 90.1M shares outstanding

10-Q filing | 86.5M shares outstanding

10-K filing | 88.9M shares outstanding

10-Q filing | 75.8M shares outstanding

10-Q filing | 72.3M shares outstanding

10-Q filing | 66.1M shares outstanding

10-K filing | 67.8M shares outstanding

S-3 filing: The filing is an S-3 shelf registration to register common stock, preferred stock and debt securities for future sale up to a total of $300,000,000.

10-Q filing | 57.9M shares outstanding

10-Q filing | 55.1M shares outstanding

10-Q filing | 54.3M shares outstanding

10-K filing | 53.2M shares outstanding

8-K filing: aTyr Pharma, Inc. entered into an underwriting agreement to issue and sell 22,225,000 shares of common stock in an underwritten public offering at a price of $2.25 per share, with an option for the underwriters to purchase an additional 3,333,750 shares, with the offering scheduled to close on February 13, 2023, and estimated gross proceeds of approximately $50.0 million. ($50.0M proceeds)

10-Q filing | 28.7M shares outstanding

10-Q filing | 28.1M shares outstanding

10-Q filing | 28.1M shares outstanding

10-K filing | 27.8M shares outstanding

S-3 filing: The company files an S-3 to register an offering for common stock, preferred stock, and debt securities, with a total offering amount of $200,000,000.

10-Q filing | 27.8M shares outstanding

8-K filing: aTyr Pharma, Inc. entered into a purchase agreement with Piper Sandler & Co. and RBC Capital Markets, LLC, to issue and sell 9,375,000 shares of common stock in an underwritten public offering at $8.00 per share, with an option for the Underwriters to purchase an additional 1,406,250 shares. ($75.0M proceeds)

10-Q filing | 16.9M shares outstanding

S-3 filing: The company is filing an S-3 to register common stock, preferred stock, and debt securities for a total offering amount of $75,000,000, which may be offered from time to time.

10-Q filing | 16.1M shares outstanding

10-K filing | 16.0M shares outstanding

S-3 filing: The company intends to offer up to $75,000,000 of any combination of common stock, preferred stock, and/or debt securities.

10-Q filing | 10.1M shares outstanding

S-1 filing: The filing is an S-1 form relating to the sale of up to 3,000,000 shares of common stock by Aspire Capital Fund, LLC, with the company potentially receiving up to $20.0 million from the sale of common stock to the selling stockholder.

8-K filing: aTyr Pharma, Inc. entered into a common stock purchase agreement with Aspire Capital Fund, LLC, providing that Aspire Capital is committed to purchase up to an aggregate of $20.0 million of shares of the Company's common stock at the Company's request from time to time during the 30 month term of the Purchase Agreement. ($20.0M proceeds)

10-Q filing | 9.5M shares outstanding

10-Q filing | 9.4M shares outstanding

10-K filing | 9.4M shares outstanding

S-1/A filing: The company is offering 2,542,372 shares of common stock, with an over-allotment option of 381,355 shares. The last reported sale price was $5.90 per share. Net proceeds are estimated to be $13.5 million.

S-1 filing: This is an S-1 filing for an offering of common stock. The last reported sale price of the common stock on January 16, 2020, was $7.06 per share. The underwriters have an option to purchase additional shares to cover over-allotments.